QA: Lixte Biotechnology Holdings INC in us_pharma/2021

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001335105_2022_Lixte_Biotechnology_Holdings_INC.pdf

Logs

warning Missing logo subcommand.report {}

Graph

Absolute values for 0001335105, Lixte Biotechnology Holdings INC

  xvar xval
0 AssetsCurrent 5,093,264
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 0
3 remainder_Assets 0
4 LiabilitiesCurrent 302,926
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 2,692,785
9 ResearchAndDevelopmentExpense 1,803,854
10 remainder_Expenses 1,229,221
11 remainder_Revenues 0
12 remainder_NetIncome 1,438
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 5,093,264
1 Liabilities 302,926
2 Expenses 5,725,860
3 Revenues 0
4 StockholdersEquity 4,790,338
5 NetIncome -5,724,422
6 ComprehensiveNetIncome -5,724,422
7 BaseVar 5,561,744
8 EconomicCapitalRatiobeforeLimitedLiability 1.75
9 EconomicCapitalRatio 2.85

Edgar->Model Mapping

Feature Distribution

Change over Time